Does biologic therapy increase serious infection risk?

2018

A recent study concluded that psoriasis patients receiving the biologic treatment infliximab (Remicade) are at a higher risk of contracting a serious infection that could lead to hospitalization, and even death, in comparison to patients receiving a non-biologic treatment alternative. Researchers concluded safer methods for treating psoriasis include exposure to topical and ultraviolet light therapies.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

March 11, 2022

Full Article Yiu Z, Ashcroft D, Evans I, McElhone K, Lunt M, Smith C, Walton S, Murphy R, Reynolds N, Ormerod A, Griffiths C, Warren

Moderate exercise and bright light treatment in overweight and obese individuals

March 11, 2022

Full Article Dunai A, Novak M, Chung S, Kayumov L, Keszei A, Levitan R, Shapiro C Obesity. 2007;15(7):1749-1757. “This randomized, controlled study is the first

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

March 11, 2022

Full Article Malanos D Stern R J Am Acad Dermatol. 2007;57(2):231-7. doi:10.1016/j.jaad.2007.04.027 A common fear associated with the use of psoralen plus ultraviolet A (PUVA)

Does biologic therapy increase serious infection risk?

Other Articles

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Moderate exercise and bright light treatment in overweight and obese individuals

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

CALL 1-800-DAAVLIN OR FILL OUT THE FORM BELOW

CALL 1-800-DAAVLIN OR
FILL OUT THE FORM BELOW